Q3 2025 EPS Estimates for Teva Pharmaceutical Industries Limited Boosted by Analyst (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) - Stock analysts at Zacks Research upped their Q3 2025 earnings per share (EPS) estimates for Teva Pharmaceutical Industries in a research report issued on Thursday, March 28th. Zacks Research analyst R. Department now forecasts that the company will earn $0.61 per share for the quarter, up from their previous forecast of $0.60. The consensus estimate for Teva Pharmaceutical Industries' current full-year earnings is $2.28 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries' Q4 2025 earnings at $0.77 EPS, FY2025 earnings at $2.39 EPS and FY2026 earnings at $2.71 EPS.

A number of other research analysts have also recently commented on TEVA. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 price target for the company in a research note on Friday, March 8th. StockNews.com upgraded Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Thursday, February 1st. Jefferies Financial Group upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and increased their price target for the company from $10.00 to $14.00 in a research note on Tuesday, January 23rd. The Goldman Sachs Group increased their price objective on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a "neutral" rating in a report on Monday, February 5th. Finally, Piper Sandler upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and increased their price objective for the company from $12.00 to $19.00 in a report on Monday, February 12th. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $13.78.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA traded down $0.32 during trading hours on Friday, reaching $14.11. The stock had a trading volume of 10,247,157 shares, compared to its average volume of 8,567,885. Teva Pharmaceutical Industries has a 12 month low of $7.09 and a 12 month high of $14.45. The stock has a market capitalization of $15.82 billion, a PE ratio of -30.02, a PEG ratio of 1.67 and a beta of 1.04. The company has a debt-to-equity ratio of 2.23, a quick ratio of 0.69 and a current ratio of 1.02. The company's 50-day moving average is $13.02 and its two-hundred day moving average is $10.91.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 31st. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.25. Teva Pharmaceutical Industries had a positive return on equity of 34.90% and a negative net margin of 3.33%. The firm had revenue of $4.46 billion during the quarter, compared to analysts' expectations of $3.97 billion.

Institutional Trading of Teva Pharmaceutical Industries

Large investors have recently made changes to their positions in the company. Money Concepts Capital Corp bought a new position in Teva Pharmaceutical Industries in the 4th quarter valued at about $25,000. Tower Research Capital LLC TRC lifted its position in Teva Pharmaceutical Industries by 1,729.5% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,787 shares of the company's stock valued at $39,000 after acquiring an additional 3,580 shares in the last quarter. US Bancorp DE lifted its position in Teva Pharmaceutical Industries by 36.5% in the 4th quarter. US Bancorp DE now owns 3,828 shares of the company's stock valued at $40,000 after acquiring an additional 1,023 shares in the last quarter. Blue Trust Inc. lifted its position in Teva Pharmaceutical Industries by 92.3% in the 4th quarter. Blue Trust Inc. now owns 4,541 shares of the company's stock valued at $46,000 after acquiring an additional 2,180 shares in the last quarter. Finally, Signaturefd LLC lifted its position in Teva Pharmaceutical Industries by 90.8% in the 3rd quarter. Signaturefd LLC now owns 5,032 shares of the company's stock valued at $51,000 after acquiring an additional 2,394 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 31,766 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $12.37, for a total transaction of $392,945.42. Following the completion of the sale, the chief accounting officer now directly owns 10,676 shares in the company, valued at approximately $132,062.12. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, VP Eric Drape sold 173,261 shares of the firm's stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $13.05, for a total value of $2,261,056.05. Following the completion of the sale, the vice president now directly owns 1 shares in the company, valued at approximately $13.05. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CAO Amir Weiss sold 31,766 shares of the firm's stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $12.37, for a total value of $392,945.42. Following the completion of the sale, the chief accounting officer now owns 10,676 shares of the company's stock, valued at $132,062.12. The disclosure for this sale can be found here. In the last ninety days, insiders sold 390,738 shares of company stock worth $5,132,766. Company insiders own 0.62% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.